BioNTech SE is leaping forward into integrating artificial intelligence and machine learning (AI/ML) into its business with the acquisition of a technology specialist company that it partnered with two years ago. In addition to beefing up BioNTech’s presence in AI/ML, an area that drug makers have increasingly invested in as a way to improve the speed and efficiency of drug discovery and development, the acquisition also may improve its competitive footing against mRNA rival Moderna, Inc., which has emphasized digital technology adoption for several years.
BioNTech Beefs Up AI/ML Investment With InstaDeep Buy
The company is spending up to £562m to acquire artificial intelligence/machine learning provider InstaDeep, which it has partnered with since 2020, as competitor Moderna has made digital technology a cornerstone of its strategy.
